Compare Moderna, Inc. (MRNA) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Moderna, Inc. trades at $63.7 (market cap $24.18B), while iShares 1 3 Year Treasury Bond ETF trades at $81.93. The key difference: Moderna, Inc. is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRNA | SHY | |
|---|---|---|
Market Cap | $24.18B | — |
Sector | Health | Fixed Income |
52-Week High | $81.80 | $83.18 |
52-Week Low | $22.36 | $81.77 |
Enterprise Value | $20.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
SHY, the iShares 1-3 Year Treasury Bond ETF, trades at $81.92, up 0.08% on the day. Technical indicators are bearish overall, with moving averages signaling sell pressure, while oscillators remain neutral. Recent news highlights institutional buying interest amid fluctuating Treasury yields driven by inflation data and geopolitical tensions.
The outlook for SHY is influenced by Federal Reserve policy expectations and inflation trends. Opportunities include its role as a short-duration bond haven during volatility, but risks involve rising yields pressuring prices and macroeconomic uncertainty. Investors should weigh interest rate sensitivity against current institutional accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
